OSAPQ — ProSomnus Share News
0.000.00%
Last trade - 00:00- $0.24m
- $27.59m
- $27.65m
Prosomnus Inc expected to post a loss of 31 cents a share - Earnings Preview
Prosomnus Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Prosomnus Raises $10 Million To Fuel Growth And Optimize Operations
Brief: Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy With Prosomnus Devices Is Non-Inferior To Cpap Therapy For The Treatment Of Moderate To Severe Obstructive Sleep Apnea
Brief: Prosomnus- On Aug 14, Got Written Notice From Nasdaq Indicating That Co Is No Longer In Compliance With Minimum Mvls Required For Continued Listing
Brief: ProSomnus Reports Record Q2 Top-Line Financial Results
Prosomnus Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Prosomnus Reports First Quarter 2023 Financial Results
Prosomnus Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Prosomnus Inc Reports Q4 Revenue Rose 38 Percent To $5.8 Million
Brief: Prosomnus® Receives Patent Allowance Covering Automated Manufacturing Process For Company’S Novel Precision Sleep Apnea Medical Devices
Brief: Prosomnus® Announces Acceptance Of Abstract At European Respiratory Society And European Sleep Research Society’S Sleep And Breathing 2023 Conference
Brief: Prosomnus Appoints Brian Dow As Chief Financial Officer
Brief: ProSomnus Appoints Brian Dow As Chief Financial Officer
Brief: Prosomnus Provides Business Update And Preliminary 2022 Revenue Guidance
Brief: Prosomnus Provides Business Update And Preliminary 2022 Revenue Guidance
Brief: Prosomnus® Announces Completion Of Enrollment In Antwerp University Hospital’S First Line Obstructive Sleep Apnea Treatment Study (Flosat)
Brief: Prosomnus Enrolls First Participant In Study Evaluating Prosomnus Evo™ In Treating Severe Obstructive Sleep Apnea
Prosomnus rises as snoring device qualifies for Medicare reimbursement